Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024)
Allogene Therapeutics (ALLO) reported FCF Margin of 247518.18% for Q1 2024, down 2193818.0% on a YoY basis from N/an in Q2 2023, and up 3.43% sequentially from 256319.05% in Q4 2023.
Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024) Analysis & Trends
Allogene Therapeutics (ALLO) has 4 years of FCF Margin data on file, last reported at 247518.18% in Q1 2024.
- For the quarter ending Q1 2024, FCF Margin fell 2193818.0% year-over-year to 247518.18%; the trailing twelve-month figure through Dec 2024 stood at 891004.55% (down 63922770.0% YoY), and the FY2024 full-year result was 891004.55%, down 63922770.0% from the prior year.
- FCF Margin advanced to 247518.18% in Q1 2024, from 256319.05% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 59.6% in Q4 2021 to a low of 276713.64% in Q2 2023.
- A 4-year average of 163894.86% and a median of 179843.59% in 2022 frame the typical range for FCF Margin.
- Peak annual rise in FCF Margin reached 2776705 bps in 2022, while the deepest fall reached 24638655 bps in 2022.
- Tracing ALLO's FCF Margin over 4 years: stood at 59.6% in 2021, then plunged by 413373 bps to 246446.15% in 2022, then decreased by 4 bps to 256319.05% in 2023, then gained by 3 bps to 247518.18% in 2024.
- Business Quant data shows ALLO's FCF Margin at 247518.18% in Q1 2024, 256319.05% in Q4 2023, and 258227.27% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -247,518.18% |
| Dec 31, 2023 | -256,319.05% |
| Sep 30, 2023 | -258,227.27% |
| Jun 30, 2023 | -276,713.64% |
| Mar 31, 2023 | -225,580.00% |
| Dec 31, 2022 | -246,446.15% |
| Sep 30, 2022 | -178,011.11% |
| Jun 30, 2022 | -67,862.50% |
| Mar 31, 2022 | -179,843.59% |
| Dec 31, 2021 | -59.60% |
| Sep 30, 2021 | -98,291.84% |
| Jun 30, 2021 | -95,629.55% |
| Mar 31, 2021 | -130.73% |